A multi-disciplinary team of UPMC clinicians has developed comprehensive clinical protocols for managing hospitalized patients exposed to xylazine—a veterinary sedative increasingly found in the unregulated opioid supply. Xylazine has been linked to severe and unique clinical complications, including difficult-to-manage withdrawal symptoms and necrotic skin ulcerations that are prone to infection and can develop into chronic, non-healing wounds.
This article was originally published on MedicalXpress.com
